Edesa Biotech
NASDAQ: EDSAMarkham, US · Founded 2015 · 23 employees on LinkedIn · 2 known investors
Find your way into Edesa Biotech
161 people in our graph share verified history with the Edesa Biotech team — schools, employers, funds. One of them is your warm intro.
Peter van der Veldenunlockedknows Par Nijhawan · together at Edesa Biotech (overlapped)
×9knows the team · via University of Ottawa
×2knows the team · via Mayo Clinic Alix School of Medicine
Edesa Biotech is a clinical-stage biopharmaceutical company developing monoclonal antibody candidates as host-directed therapeutics for inflammatory and immune-related diseases. Its pipeline targets conditions such as Acute Respiratory Distress Syndrome (ARDS) by modulating immune pathways implicated across multiple diseases.
Founders & leadership
Edesa Biotech was founded in 2015 by Pardeep Nijhawan.
PN
Pardeep NijhawanFounder
SL
Stephen LemieuxinCFO2023–2025
MB
Michael BrooksExecutive
MC
Mary Catherine BrissonExecutive
MA
Mark A. McPartlandExecutive
KN
Kathi NiffeneggerinFinance Advisor2023–2024
PN
Par NijhawaninChief Executive OfficerHe completed medical residency and fellowship training at Mayo Clinic School of Medicine and has prior experience in pharmaceuticals, commercial strategy, and drug development.
Board
PM
Patrick MarshallBoard director
SM
Sean MacDonaldBoard director
CO
Charles OlsonBoard director
FO
Frank OakesBoard director
DL
David LiuBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$25.2M disclosed across 3 of 4 rounds · 2016–2026
▶$3.5MraisedJun 2026 · 4 investors · BiotechnologyRule 506(b)
▶$3.5MraisedJun 2026 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joan ChypyhaDirector
- Sean MacDonaldDirector
- David LiuDirector
- Peter WeilerExecutive Officer
- Carlo SistilliDirector
- Pardeep NijhawanExecutive Officer, Director
- Michael BrooksExecutive Officer
- Patrick MarshallDirector
- Charles OlsonDirector
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- First sale
- Jun 2026
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$15MraisedFeb 2025 · 15 investors · BiotechnologyRule 506(b)
▶$15MraisedFeb 2025 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick MarshallDirector
- Sean MacDonaldDirector
- Pardeep NijhawanExecutive Officer, Director
- Stephen LemieuxExecutive Officer
- Charles OlsonDirector
- Frank OakesDirector
- David LiuDirector
- Joan ChypyhaDirector
- Michael BrooksExecutive Officer
- Carlo SistilliDirector
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Feb 2025
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶Undisclosed amountofferedApr 2022 · 1 investors · BiotechnologyRule 506(b)
▶Undisclosed amountofferedApr 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael BrooksExecutive Officer
- Kathi NiffeneggerExecutive Officer
- Sean MacDonaldDirector
- Paul PayDirector
- Carlo SistilliDirector
- Jennifer ChaoDirector
- Pardeep NijhawanExecutive Officer, Director
- Lorin JohnsonDirector
- Frank OakesDirector
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Mar 2022
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$6.8MraisedJul 2016 · 4 investors · BiotechnologyRule 506(c)
▶$6.8MraisedJul 2016 · 4 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- David Louis HillDirector
- Mayank D. SampatDirector
- Tessie M. CheDirector
- Daniel E. MorseDirector
- Frank R. OakesExecutive Officer, Director
- Mary Catherine BrissonExecutive Officer
- Gregory T. BaxterDirector
- Mark A. McPartlandExecutive Officer
- Kathi NiffeneggerExecutive Officer
- Offering amount
- $6.8M
- Amount sold
- $6.8M
- Sales commissions
- $472.5K
- Placement agents
- Maxim Group LLC
- First sale
- Jul 2016
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlap
Robinhood18 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits18 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Public17 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
TradingView15 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Simply Wall St14 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Gotrade14 shared keywordsGotrade is a fractional stock trading platform that allows users to buy shares of major companies like Google, Apple, and Netflix with investments starting from $1. The platform serves retail investors globally and is regulated for account protection up to USD 500,000.
Seeking Alpha14 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Edesa Biotech for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Edesa Biotech (EDSA) details $3.5M private placement and 729,241-share resalestocktitan.net · Jul 2026
Edesa Biotech, Inc. Announces $3.5 Million PIPE Financing to Advance Clinical Programs | Quiver Quantitativequiverquant.com · Jun 2026
Edesa Biotech enters $3.5M PIPE led by CEO | EDSA Stock Newsstocktitan.net · Jun 2026Frequently asked questions
- What does Edesa Biotech do?
- Edesa Biotech is a clinical-stage biopharmaceutical company developing monoclonal antibody candidates as host-directed therapeutics for inflammatory and immune-related diseases. Its pipeline targets conditions such as Acute Respiratory Distress Syndrome (ARDS) by modulating immune pathways implicated across multiple diseases.
- Who founded Edesa Biotech?
- Edesa Biotech was founded by Pardeep Nijhawan in 2015.
- Who are Edesa Biotech's investors?
- Edesa Biotech's investors include Lumira Ventures, Venture Ontario.
- How much funding has Edesa Biotech raised?
- Edesa Biotech has disclosed $25.2M raised across 3 of its 4 known rounds.
- Where is Edesa Biotech headquartered?
- Edesa Biotech is headquartered in Markham, US.